Project Details
Description
Antiretroviral therapy (ART) is recommended for all people living with HIV (PLWH) – regardless of their CD4
cell count – to improve survival and reduce transmission. This “treat-all” approach benefits PLWH overall, but
also confers a risk of unmasking immune reconstitution inflammatory syndrome (IRIS) and death, particularly
for the 30-40% of people who present with advanced HIV disease (CD4 count 200 of
| Status | Active |
|---|---|
| Effective start/end date | 8/23/21 → 7/31/24 |
Funding
- National Institute of Allergy and Infectious Diseases: $626,433.00
- National Institute of Allergy and Infectious Diseases: $662,335.00
- National Institute of Allergy and Infectious Diseases: $630,069.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.